

Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/C692FC9648B7EN.html>

Date: March 2022

Pages: 106

Price: US\$ 2,000.00 (Single User License)

ID: C692FC9648B7EN

Abstracts

Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Colitis (Gastrointestinal) pipeline landscape.

Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn's disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the

therapeutics, its complete research and development history and latest news and press releases.

The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 3, 1, 28 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Colitis - Overview
Colitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Colitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Colitis - Companies Involved in Therapeutics Development
9 Meters Biopharma Inc
Aclaris Therapeutics Inc
Alfasigma SpA
Amgen Inc
Apollo Endosurgery Inc
Artus Therapeutics Inc
Chiesi Farmaceutici SpA
Citryll BV
Dr. Falk Pharma GmbH
Drug Farm Inc
Elgia Therapeutics Inc
enGene Inc
F. Hoffmann-La Roche Ltd
First Wave BioPharma Inc
Himuka AM Pharma Corp
Immodulon Therapeutics Ltd
Immuron Ltd
Jubilant Therapeutics Inc
MAKScientific LLC
Nippon Kayaku Co Ltd
Privo Technologies Inc
Protagonist Therapeutics Inc

Protheragen Inc
Riptide Bioscience Inc
Scholar Rock Inc
Servatus Ltd
Soligenix Inc
Symbiotix Biotherapies Inc
TaiRx Inc
TPCera Ltd
Vascular Biogenics Ltd
Vedanta Biosciences Inc
Vitality Biopharma Inc
Wuhan LL Science and Technology Development Co Ltd
Colitis - Drug Profiles
(cannabidiol + hydroxychloroquine) - Drug Profile
Product Description
Mechanism Of Action
AcTMP-1 - Drug Profile
Product Description
Mechanism Of Action
ARTX-28 - Drug Profile
Product Description
Mechanism Of Action
ATI-2138 - Drug Profile
Product Description
Mechanism Of Action
beclomethasone dipropionate SR - Drug Profile
Product Description
Mechanism Of Action
budesonide - Drug Profile
Product Description
Mechanism Of Action
History of Events
CIT-013 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DF-004 - Drug Profile
Product Description
Mechanism Of Action

Drugs to Antagonize TRP Channel for Inflammatory Diseases and Colitis - Drug Profile

Product Description

Mechanism Of Action

dusquetide - Drug Profile

Product Description

Mechanism Of Action

History of Events

FW-420 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate PD-L1 for Colitis and Graft Versus Host Disease - Drug Profile

Product Description

Mechanism Of Action

HM-201 - Drug Profile

Product Description

Mechanism Of Action

IMM-124E - Drug Profile

Product Description

Mechanism Of Action

History of Events

IMM-201 - Drug Profile

Product Description

Mechanism Of Action

JBI-1044 - Drug Profile

Product Description

Mechanism Of Action

MAK-11049 - Drug Profile

Product Description

Mechanism Of Action

MCC-950 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibodies to Inhibit LTC₄ for Colitis - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibodies to Inhibit TGFB1 for Oncology, Gastrointestinal and Genito

Urinary System and Sex Hormones Diseases - Drug Profile

Product Description

Mechanism Of Action

History of Events

MY-007 - Drug Profile

Product Description

Mechanism Of Action

MY-009 - Drug Profile

Product Description

Mechanism Of Action

niclosamide - Drug Profile

Product Description

Mechanism Of Action

History of Events

NK-007 - Drug Profile

Product Description

Mechanism Of Action

Peptide to Inhibit NFkB for Colitis and Enteritis - Drug Profile

Product Description

Mechanism Of Action

PN-1140 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PRV-331 - Drug Profile

Product Description

Mechanism Of Action

R-491 - Drug Profile

Product Description

Mechanism Of Action

RDD-2007 - Drug Profile

Product Description

Mechanism Of Action

rifaximin - Drug Profile

Product Description

Mechanism Of Action

History of Events

RP-182 - Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Colitis and Arthritis - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit Caspase 1 for Colitis, Inflammatory Bowel Disease and Neuroinflammation - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Target Androgen Receptor and Glucocorticoid Receptor for Oncology, Autoimmune diseases and Inflammatory Disorders - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit 15-PGDH for Colitis and Idiopathic Pulmonary Fibrosis - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit Sphingosine Kinase for Colorectal Cancer and Colitis - Drug Profile

Product Description

Mechanism Of Action

SVT-1E167 - Drug Profile

Product Description

Mechanism Of Action

SVT-3A4710 - Drug Profile

Product Description

Mechanism Of Action

SYMB-104 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SYMB-202 - Drug Profile

Product Description

Mechanism Of Action

tacrolimus - Drug Profile

Product Description

Mechanism Of Action

TPC-1022 - Drug Profile

Product Description

Mechanism Of Action

TRX-105 - Drug Profile

Product Description

Mechanism Of Action

VB-100 - Drug Profile

Product Description

Mechanism Of Action

History of Events

VB-601 - Drug Profile

Product Description

Mechanism Of Action

VE-303 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Colitis - Dormant Projects

Colitis - Discontinued Products

Colitis - Product Development Milestones

Featured News & Press Releases

Oct 21, 2021: First Wave BioPharma forms steering committee for Phase 2a PASSPORT clinical trial to evaluate FW-ICI-AC in cancer patients with immune checkpoint inhibitor-associated colitis

Oct 19, 2021: First Wave BioPharma announces FDA clearance of IND application for phase 2a PASSPORT trial of FW-ICI-AC as treatment for immune checkpoint inhibitor-associated colitis

Sep 08, 2021: AzurRx BioPharma submits an investigational new drug application for niclosamide as treatment for grade 1 and grade 2 immune checkpoint inhibitor-associated colitis

Apr 13, 2021: AzurRx BioPharma engages PPD to manage clinical trial for niclosamide as treatment for grade 1 immune checkpoint inhibitor-associated colitis

May 06, 2020: VBL presents new data on MOSPD2 antibodies as potential treatment for NASH and colitis at DDW

May 10, 2018: Vitality's GI-targeted VBX-100 THC compound to be investigated as treatment of recurrent difficile infections

May 07, 2018: Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program

Feb 05, 2018: Tillotts Pharma announces MHRA approval of Entocort Capsules for Microscopic Colitis

Feb 05, 2018: Tillotts Pharma announces MHRA approval of Entocort Capsules for

Microscopic Colitis

Aug 07, 2017: Case Western Reserve University researchers develop therapeutic to enhance tissue repair and regeneration

Jul 19, 2017: Vitality Biopharma Releases Positive Results for Treatment of Inflammatory Bowel Disease

Apr 18, 2017: Immuron Announces Positive Results of IMM-124E in Acute Colitis Research Studies

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Colitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Colitis - Pipeline by 9 Meters Biopharma Inc, 2022
Colitis - Pipeline by Aclaris Therapeutics Inc, 2022
Colitis - Pipeline by Alfasigma SpA, 2022
Colitis - Pipeline by Amgen Inc, 2022
Colitis - Pipeline by Apollo Endosurgery Inc, 2022
Colitis - Pipeline by Artus Therapeutics Inc, 2022
Colitis - Pipeline by Chiesi Farmaceutici SpA, 2022
Colitis - Pipeline by Citryll BV, 2022
Colitis - Pipeline by Dr. Falk Pharma GmbH, 2022
Colitis - Pipeline by Drug Farm Inc, 2022
Colitis - Pipeline by Elgia Therapeutics Inc, 2022
Colitis - Pipeline by enGene Inc, 2022
Colitis - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Colitis - Pipeline by First Wave BioPharma Inc, 2022
Colitis - Pipeline by Himuka AM Pharma Corp, 2022
Colitis - Pipeline by Immodulon Therapeutics Ltd, 2022
Colitis - Pipeline by Immuron Ltd, 2022
Colitis - Pipeline by Jubilant Therapeutics Inc, 2022
Colitis - Pipeline by MAKScientific LLC, 2022
Colitis - Pipeline by Nippon Kayaku Co Ltd, 2022
Colitis - Pipeline by Privo Technologies Inc, 2022
Colitis - Pipeline by Protagonist Therapeutics Inc, 2022
Colitis - Pipeline by Protheragen Inc, 2022
Colitis - Pipeline by Riptide Bioscience Inc, 2022

Colitis - Pipeline by Scholar Rock Inc, 2022
Colitis - Pipeline by Servatus Ltd, 2022
Colitis - Pipeline by Soligenix Inc, 2022
Colitis - Pipeline by Symbiotix Biotherapies Inc, 2022
Colitis - Pipeline by TaiRx Inc, 2022
Colitis - Pipeline by TPCera Ltd, 2022
Colitis - Pipeline by Vascular Biogenics Ltd, 2022
Colitis - Pipeline by Vedanta Biosciences Inc, 2022
Colitis - Pipeline by Vitality Biopharma Inc, 2022
Colitis - Pipeline by Wuhan LL Science and Technology Development Co Ltd, 2022
Colitis - Dormant Projects, 2022
Colitis - Dormant Projects, 2022 (Contd..1)
Colitis - Dormant Projects, 2022 (Contd..2)
Colitis - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Colitis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/C692FC9648B7EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C692FC9648B7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

